22.12.2012 Views

Emerging Business Models in the Pharmaceutical Industries ...

Emerging Business Models in the Pharmaceutical Industries ...

Emerging Business Models in the Pharmaceutical Industries ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Geographic Overview<br />

Introduction<br />

North America is <strong>the</strong> major pharma market, but Europe is also<br />

receiv<strong>in</strong>g <strong>in</strong>creased attention from <strong>the</strong> ma<strong>in</strong> players. While <strong>the</strong><br />

geographic behaviour of <strong>the</strong> pharma market is directly proportionate<br />

to a country’s spend<strong>in</strong>g capacity, awareness, and government<br />

regulations, while size of population does not have any real effect.<br />

North America - Lead<strong>in</strong>g Pharma Market<br />

North America is <strong>the</strong> largest pharma market and has <strong>the</strong> least<br />

restrictions. America has larger fund<strong>in</strong>g than European and Asian<br />

countries, and growth is expected to cont<strong>in</strong>ue. R&D <strong>in</strong>vestment is<br />

also higher, with 13 approved NME companies. Companies <strong>in</strong> <strong>the</strong><br />

US show <strong>in</strong>creas<strong>in</strong>g export sales. The ban on drug imports from<br />

Canada is believed to have resulted <strong>in</strong> w<strong>in</strong>dfall profits of $150 billion<br />

for <strong>the</strong> US pharmaceutical <strong>in</strong>dustry, and <strong>the</strong> issue has provoked<br />

passionate debate on campaign trails.<br />

European Pharma Industry Ga<strong>in</strong><strong>in</strong>g Momentum<br />

The EU countries comprise <strong>the</strong> second largest market for pharma<br />

companies. Saturation <strong>in</strong> <strong>the</strong> North American market has led all <strong>the</strong><br />

pharma companies to focus on <strong>the</strong> EU market. However, s<strong>in</strong>ce <strong>the</strong><br />

government is <strong>the</strong> biggest drug buyer <strong>in</strong> <strong>the</strong> EU, it can impose<br />

restrictions on <strong>the</strong> pric<strong>in</strong>g and profits of pharma companies.<br />

This year <strong>the</strong> European market has been affected by <strong>the</strong> new<br />

Refund list, cuts <strong>in</strong> regulated drug prices, grow<strong>in</strong>g market<br />

competition, and tax cuts. "The market is grow<strong>in</strong>g more slowly than<br />

we expected this year. But <strong>in</strong> <strong>the</strong> future Poland will be one of<br />

Europe's most attractive drug markets. I expect it to grow by 8-10%<br />

<strong>in</strong> <strong>the</strong> com<strong>in</strong>g years“, says Jacek Szwajcowski, chief executive of<br />

PGF, Poland's largest drug distributor.<br />

Billion US $<br />

250<br />

200<br />

150<br />

100<br />

50<br />

Geographic Distribution of <strong>the</strong> Pharma<br />

Market Size<br />

Strategic Analysis of <strong>the</strong> Pharma Market, Future Revenue <strong>Models</strong> and Key Players 16<br />

16%<br />

0<br />

6% 6%<br />

24%<br />

North America<br />

48%<br />

North America<br />

Europe<br />

Japan<br />

Key Geographic Markets<br />

Europe<br />

Source: JSB Intelligence<br />

Japan<br />

Asia, Africa and Australia<br />

Asia, Africa and<br />

Australia<br />

Lat<strong>in</strong> America<br />

Lat<strong>in</strong> America<br />

2000<br />

2001<br />

2002<br />

2003

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!